会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 피리다지논, 피리미돈 또는 피리돈 구조를 포함하는선택적인 트롬빈 억제제
    • 基于吡咯烷酮,吡咯烷酮或吡咯烷酮的选择性硫蛋白抑制剂
    • KR1020070095236A
    • 2007-09-28
    • KR1020070027069
    • 2007-03-20
    • 주식회사 엘지생명과학
    • 박태교이현호박종우송호영최증순박희동김태훈김경희이태수장민선이재익권태식하용화서동욱최윤희이정애오영수백승엽김형진박미정윤하식정수용
    • C07D237/14C07D237/22C07D401/10
    • A novel compound is provided to secure excellent thrombin inhibitory activity and excellent selectivity on the thrombin and is able to be orally absorbed. And a method for preparing the same and a pharmaceutical composition comprising the same are provided. A compound is represented by the formula(1), wherein A is N or CR^1, B is N or CR^2, each R^3 and R^4 is H, OH, halogen, CN, CF3, or C1-8 alkyl, or R^3 and R^4 together with a carbon atom attached thereto forms C=O, 3 to 8 membered cycloalkyl, or 3 to 8 membered heterocycle having at least one atom selected from the group consisting of N, O and S, R^5 is (a) H, (b) halogen, (c) CN or CH2CN, (d) CF3, OR^6, S(O)0-2R^6, C(=O)R^6, S(O)2NHR^6, and NR^6R^6a, (e) halogen, CN, CF3, OH, and phenyl substituted or unsubstituted by C1-4 alkoxy, (f) halogen, OH, CN, C1-8 alkoxy, COOH, COO-C1-8 alkyl and C1-8 alkyl mono-substituted or poly-substituted by COO-C1-8 alkyl, (g) halogen, OH, CN, C1-8 alkoxy, COOH, COO-C1-8 alkyl and 3 to 8 membered cycloalkyl mono-substituted or poly-substituted by COO-C1-8 alkyl, or (h) 3 to 8 membered heterocycle or 5 to 8 membered heteroaryl including at least one hetero atom selected from the group consisting of N, O and S, m is an integer from 0 to 3, n is an integer from 1 to 6, k is an integer from 0 to 3, and P1 is C1-8 alkyl substituted or unsubstituted by one or two radicals selected from R^7 and R^7, C2-8 alkenyl, 3 to 8 membered cycloalkyl, 4 to 8 membered cycloalkenyl, phenyl, 3 to 8 membered heterocycle including 1-5 heteroatoms selected from the group consisting of N, O and S, or 5 to 8 membered heteroaryl including 1-5 heteroatoms selected from the group consisting of N, O and S.
    • 提供了一种新颖的化合物以确保优良的凝血酶抑制活性和对凝血酶的优异选择性,并且能够被口服吸收。 并提供其制备方法和包含其的药物组合物。 化合物由式(1)表示,其中A是N或CR 1,B是N或CR 2,每个R 3和R 4是H,OH,卤素,CN,CF 3或C1- 8烷基或R 3和R 4与连接的碳原子一起形成C = O 3至8元环烷基或具有至少一个选自N,O的原子的3至8元杂环,以及 S,R 5是(a)H,(b)卤素,(c)CN或CH 2 CN,(d)CF 3,OR 6,S(O)0-2R 6,C(= O) ,(C)卤素,CN,CF 3,OH和被C 1-4烷氧基取代或未取代的苯基,(f)卤素,OH,CN,C 1-8 烷氧基,COOH,COO-C 1-8烷基和被COO-C 1-8烷基单取代或多取代的C 1-8烷基,(g)卤素,OH,CN,C 1-8烷氧基,COOH,COO- 8烷基和3至8元环烷基,其被COO-C 1-8烷基单取代或多取代,或(h)3至8元杂环或5至8元杂芳基,包括至少一个选自以下的杂原子: N,O和S,m为0〜3的整数,n为整数 r为1至6,k为0至3的整数,P1为被一个或两个选自R 7和R 7的基团取代或未取代的C 1-8烷基,C 2-8链烯基,3至8元环烷基 ,4至8元环烯基,苯基,3至8元杂环,包括1-5个选自N,O和S的杂原子,或5至8元杂芳基,包括1-5个选自N, O和S.
    • 4. 发明公开
    • 이소옥사졸린 구조를 갖는 캐스파제 저해제
    • CASPASE抑制剂含有具有由CASPAS引起的治疗或缓解症状的改善活性的异丙嗪环,包括炎症或病毒性
    • KR1020050022364A
    • 2005-03-07
    • KR1020040066726
    • 2004-08-24
    • 주식회사 엘지생명과학
    • 장혜경오영수박철원장용진박태교김성섭김민정박미정박정규박희동민경식이태수이상균김수헌정희경이선화김화동김애리박기숙신현익최형욱이규웅이재훈허태호김호준권태식
    • C07D261/04C07D413/12
    • C07D261/04C07D413/04C07D413/12C07D413/14
    • PURPOSE: Caspase inhibitors containing an isoxazoline ring are provided, which caspase inhibitors have improved activity of treating or alleviating sympthoms caused by the caspase including inflammation or apoptosis. CONSTITUTION: The caspase inhibitors containing an isoxazoline ring, represented by formula (1), salts thereof or stereochemical isomers thereof are provided, wherein R is H, simple alkyl chain(-SAC), simple cycloalkyl chain(-SCAC), aryl(-Ar) or aryl substituted simple alkyl chain(-SAC-Ar); R1 is -CH2COOH, -CH2COOR3(R3 = SAC) or -CH2CONHSO2R4(R4 = SAC); R2 is H, -SAC, -Ar or -(CH2)nOR7(R7 = -SAC, -SCAC, -Ar or -SAC-Ar, and n = 1 or 2); A is -(CH2)n- (n = 0-4), -O-(CH2)n- (n = 0-4) or -NR 9-(CH2)n-(n = 0-4, and R9 is -SAC, -SCAC, -Ar or -SAC-Ar); B is H, -SAC, -SCAC, -Ar or -SAC-Ar; -R-R1 is -(CH2)n-, -(CH2)n-O-(CH 2)m- or -(CH2)n-NR10-(CH2)m-(n+m
    • 目的:提供含有异恶唑啉环的胱天蛋白酶抑制剂,其中胱天蛋白酶抑制剂具有改善的治疗或减轻由胱天蛋白酶引起的症状(包括炎症或细胞凋亡)的活性。 提供含有式(1)表示的异恶唑啉环的胱天蛋白酶抑制剂,其盐或其立体化学异构体,其中R为H,简单烷基链(-SAC),简单环烷基链(-SCAC),芳基( - Ar)或芳基取代的简单烷基链(-SAC-Ar); R1是-CH2COOH,-CH2COOR3(R3 = SAC)或-CH2CONHSO2R4(R4 = SAC); R2是H,-SAC,-Ar或 - (CH2)nOR7(R7 = -SAC,-SCAC,-Ar或-SAC-Ar,n = 1或2)。 A是 - (CH 2)n - (n = 0-4),-O-(CH 2)n - (n = 0-4)或-NR 9 - (CH 2)n - (n = 0-4, 是-SAC,-SCAC,-Ar或-SAC-Ar); B是H,-SAC,-SCAC,-Ar或-SAC-Ar; -R-R 1是 - (CH 2)n - , - (CH 2)n O-(CH 2)m-或 - (CH 2)n -NR 10 - (CH 2)m - (n + m <9,R 10 = -SAC ,-SCAC,-Ar,-SAC-Ar,-C(= O)-SAC,-C(= O)-SSCAC,-C(= O)-Ar或-C(= O)-SAC-Ar) ; X是-C(= O)CH 2 O 2,-C(= O)CH 2 OC(= O)Ar或-COCH 2 -W(W是-N 2,-F,-Cl,-Br,-I,-NR 15 R 16(R 15和 R 16是独立的-SAC,-SCAC,-Ar或-SAC-Ar)或形成3至6元环饱和或不饱和的环状基团或-SR 17(R 17 = -SAC,-SCAC,-Ar或-SAC- Ar); Y是H,-OH,-OR 18(R 18 = -SAC,-SCAC),-C(= O)R 19(R 19 = -H,-SAC,-SCAC),-F,-Cl,-Br ,-I,-CN,-NC,-N3,-CO2H,CF3,-CO2R20(R20 = -SAC,-SCAC),-C(= O)NHR21(R21 = -SAC,-SCAC)或-C = O)NR22R23(R22和R23独立为-SAC,-SCAC,-Ar或-SAC-Ar)); 和R 24是H,-SAC,-SAC-Ar或-Ar。
    • 5. 发明公开
    • 신규한 파네실 전이효소 억제제 및 그의 제조방법
    • 具有吡咯环和抑制农药转移的新型化合物,药物可接受的盐,水合物,溶剂和异构体,其制备方法
    • KR1020040083150A
    • 2004-10-01
    • KR1020030017705
    • 2003-03-21
    • 주식회사 엘지생명과학
    • 홍창용이진호이인상이성배김종현최세현김학중최환근한희운정신우김동명박지현김민형구선영김경희이선화최옥희권태식
    • C07D401/14
    • PURPOSE: A novel compound having the pyrrole ring and inhibiting farnesyl transferase, its pharmaceutically acceptable salt, hydrate, solvate and isomer are provided. And their preparation method is also provided. The farnesyl transferase inhibitors have anticancer activity, restenosis inhibiting activity, hyperlipidemia inhibiting activity and antiviral activity. CONSTITUTION: The compound as a farnesyl transferase inhibitor is represented by the formula(1), wherein n is 0, 1 or 2; X is C or N; R1 is hydrogen or methyl; R2 is lower alkyl, halogen optionally substituted phenyl, or naphthyl; and R3 is selected from the formula of N-R5-N-R5-R6, N-R5-Y-R6 or N-Y ring in which Y is O, S, S=O or SO2, R5 and R6 are independently hydrogen, hydroxyl, lower alkyl or lower alkoxy, and R4 is lower alkyl, alkoxyalkyl, cycloalkyl, cycloalkyl substituted lower alkyl or hetero aromatic ring substituted lower alkyl, or OR7 in which R7 is lower alkyl, alkoxyalkyl, morpholinyl, morpholinyl substituted lower alkyl, N-methylpiperazinyl substituted lower alkyl or alkenyl. The method for preparing the compound of the formula(1) comprises the steps of: reacting a compound of the formula(2) with (a) L-R4 in which L is halogen, (b) CHO-R4 or ketone compound in the presence of sodium triacetoxy borohydride, or (c) L-C(O)(CH2)n-L in which n is an integer of 1 to 5; and substituting the reaction product with morpholine or piperazine.
    • 目的:提供具有吡咯环和抑制法呢基转移酶,其药学上可接受的盐,水合物,溶剂合物和异构体的新型化合物。 并提供其制备方法。 法呢基转移酶抑制剂具有抗癌活性,再狭窄抑制活性,高脂血症抑制活性和抗病毒活性。 构成:法呢基转移酶抑制剂的化合物由式(1)表示,其中n为0,1或2; X为C或N; R1是氢或甲基; R2是低级烷基,卤素任意取代的苯基或萘基; 并且R 3选自其中Y为O,S,S = O或SO 2的N-R5-N-R5-R6,N-R5-Y-R6或NY环,R5和R6独立地为氢,羟基 低级烷基或低级烷氧基,R4为低级烷基,烷氧基烷基,环烷基,环烷基取代的低级烷基或杂芳环取代的低级烷基,或OR7,其中R7为低级烷基,烷氧基烷基,吗啉基,吗啉基取代的低级烷基,N-甲基哌嗪基 取代的低级烷基或烯基。 制备式(1)化合物的方法包括以下步骤:使式(2)化合物与(a)L-R4(其中L是卤素)反应,(b)CHO-R4或酮化合物在 三氯乙酰氧基硼氢化钠的存在,或(c)LC(O)(CH2)nL,其中n为1至5的整数; 并用吗啉或哌嗪代替反应产物。
    • 6. 发明公开
    • 파네실 전이효소 억제제, 그의 제조방법 및 그를 함유하는약제학적 조성물
    • 农药转移抑制剂,其制备方法和含有该化合物的药物组合物,其中该化合物可用于预防和治疗癌症,病毒或高脂血症
    • KR1020040087602A
    • 2004-10-14
    • KR1020030022047
    • 2003-04-08
    • 주식회사 엘지생명과학
    • 홍창용이진호이인상이성배김종현최세현김학중최환근한희운정신우김동명박지현김민형구선영김경희이선화최옥희권태식
    • C07D413/14
    • PURPOSE: Farnesyl transferase inhibitors, preparation processes thereof and pharmaceutical compositions containing the same compounds are provided, which compounds have improved farnesyl transferase inhibiting activity and low CYP 3A4 enzyme inhibiting activity, so that an interaction between drugs for farnesyl transferase and CYP 3A4 enzyme can be minimized, and the compounds can be useful for prevention and treatment of cancer, virus or hyperlipidemia. CONSTITUTION: The farnesyl transferase inhibitors represented by formula (1), or pharmaceutically acceptable salts or isomers thereof are provided, wherein (B) is one selected from benzene ring, N-benzene ring, Y-benzene ring and X-Y-benzene ring; X and Y are independently C-H, N, O or S; R1 and R2 are independently hydrogen, optionally halogen substituted C1-6 alkyl, optionally halogen substituted C1-6 alkoxy, hydroxy, halogen, nitro, cyano, thienyl, C3-6 cycloalkyl, di(C1-6alkyl)amine, C3-6 cycloamine, C3-6 cycloalkylamine, C5-6 heterocycloamine, C5-6 heterocycloalkylamine, optionally C1-6 alkyl or halogen substituted phenoxy, or optionally C1-6 alkyl or halogen substituted aniline, or a compound of formula (2); X' is C-H or N; R6, R7, R8 and R9 are independently hydrogen, C1-6 alkyl, C1-6alkoxy, hydroxy, halogen, nitro, cyano, amino or di(C1-6alkyl)amine; R3 is C1-6 alkyl; R4 is optionally C2-6 alkenyl or halogen substituted phenyl or naphthyl; R5 is one selected from R10-N-N-R10R11, R10-N-Y'-R11 and N-Y'-benzene ring; Y' is O, S, S=O or SO2; and R10 and R11 are independently hydrogen, hydroxy, C1-6 alkyl or C1-6 alkoxy.
    • 目的:提供法呢基转移酶抑制剂,其制备方法和含有相同化合物的药物组合物,该化合物具有改善的法呢基转移酶抑制活性和低CYP 3A4酶抑制活性,使得法呢基转移酶和CYP 3A4酶的药物之间的相互作用可以是 并且该化合物可用于预防和治疗癌症,病毒或高脂血症。 构成:提供由式(1)表示的法呢基转移酶抑制剂或其药学上可接受的盐或异构体,其中(B)选自苯环,N-苯环,Y-苯环和X-Y-苯环中的一种; X和Y独立地为C-H,N,O或S; R 1和R 2独立地为氢,任选卤素取代的C 1-6烷基,任选卤素取代的C 1-6烷氧基,羟基,卤素,硝基,氰基,噻吩基,C 3-6环烷基,二(C 1-6烷基)胺,C 3-6环胺 C 3-6环烷基胺,C 5-6杂环基,C 5-6杂环烷基胺,任选C 1-6烷基或卤素取代的苯氧基,或任选的C 1-6烷基或卤素取代的苯胺,或式(2)的化合物; X'是C-H或N; R6,R7,R8和R9独立地是氢,C1-6烷基,C1-6烷氧基,羟基,卤素,硝基,氰基,氨基或二(C1-6烷基)胺; R3是C1-6烷基; R4任选为C 2-6烯基或卤素取代的苯基或萘基; R5是选自R10-N-N-R10R11,R10-N-Y'-R11和N-Y'-苯环的一个; Y'是O,S,S = O或SO 2; R 10和R 11独立地是氢,羟基,C 1-6烷基或C 1-6烷氧基。